Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities
June 06 2022 - 9:00AM
Business Wire
Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell
biology, and Curia, formerly AMRI, a leading contract research,
development and manufacturing organization (CDMO), today announced
Curia’s adoption of The Beacon® Optofluidic system and workflows
from Berkeley Lights to accelerate and expand its antibody-based
drug discovery capabilities.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220606005164/en/
The Beacon system workflow at Curia leverages its proprietary
Pentamice® platform, CHO-GSN℠ and TunaCHO℠ platforms,
as well as the company’s antibody and cell-line engineering
systems. The Pentamice® platform, CHO-GSN℠ and TunaCHO℠
platforms were developed at LakePharma, which Curia acquired in
2021. Learn more at curiaglobal.com/beacon.
With the addition of the Beacon system, Curia is able to provide
a seamless and comprehensive portfolio of state-of-the-art
technologies and experience for rapid progression of client
antibody programs. Its solutions address the earliest stage of
discovery, through maturation and development, to manufacture of
drug substance and final drug products under GMP.
“Speed counts in drug discovery, so the ability to conduct
high-throughput, single-cell experiments is a game changer,
enabling abundant and diverse leads,” said Christopher Conway,
president, R&D, Curia. “Advanced technologies such as the
Berkeley Lights platform are revolutionizing antibody discovery,
tackling key pain points that confront innovators, such as long
timelines and limited number of sequences. Our demonstrated ability
to integrate technologies, process and scientific expertise
ultimately enables us to accelerate the time to clinic and the
advance of life-changing life science.”
Curia scientists evaluated a variety of technologies and
selected the Beacon system based on its proven capabilities and
seamless integration in Curia’s end-to-end manufacturing value
chain. With its abilities to deliver against a range of targets
that fail with traditional technologies, combined with the proven
immunological diversity inherent in its PentaMice® platform, Curia
expects to deliver unique and diverse antibody sequences with
comprehensive data analysis under timelines that are weeks in
duration rather than months, and development candidates in six
months or fewer.
“We are excited to partner with Curia, a leading CDMO, in their
adoption of the Berkeley Lights platform for antibody discovery.
They can now accelerate the timeline in which critical therapeutics
can make it to the clinic,” said Eric Hobbs, Ph.D., president of
Antibody Therapeutics at Berkeley Lights. “Curia is showing their
commitment to adopting cutting-edge technologies that more rapidly
and effectively find the best cells, especially for
hard-to-identify antibodies.”
About Curia
Curia, formerly AMRI, is a leading contract research,
development and manufacturing organization providing products and
services from R&D through commercial manufacturing to
pharmaceutical and biopharmaceutical customers. Curia’s 3,700
employees at 29 locations across the U.S., Europe and Asia help its
customers advance from curiosity to cure. Learn more at
CuriaGlobal.com.
About Berkeley Lights
Berkeley Lights is a leading digital cell biology company
focused on enabling and accelerating the rapid development and
commercialization of biotherapeutics and other cell-based products
for our customers. The Berkeley Lights Platform captures deep
phenotypic, functional and genotypic information for thousands of
single cells in parallel and can also deliver the live biology
customers desire in the form of the best cells. Our platform is a
fully integrated, end-to-end solution, comprising proprietary
consumables, including our OptoSelect™ chips and reagent kits,
advanced automation systems, and application software. We developed
the Berkeley Lights Platform to provide the most advanced
environment for rapid functional characterization of single cells
at scale, the goal of which is to establish an industry standard
for our customers throughout their cell-based product value
chain.
Berkeley Lights’ Beacon® and Lightning™ systems and
Culture Station™ instrument are FOR RESEARCH USE ONLY. Not
for use in diagnostic procedures.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Berkeley Lights
or its products, they are forward-looking statements reflecting the
current beliefs and expectations of management. Such
forward-looking statements involve substantial known and unknown
risks and uncertainties that relate to future events, and actual
results and product performance could differ significantly from
those expressed or implied by the forward-looking statements.
Berkeley Lights undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties relating to the Company’s growth and continual
evolution see the statements in the "Risk Factors" sections, and
elsewhere, in our filings with the U.S. Securities and Exchange
Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220606005164/en/
Media:
Curia Sue Zaranek +1 518 512 2111
corporatecommunications@CuriaGlobal.com
Berkeley Lights Media – media@berkeleylights.com Investors –
IR@berkeleylights.com
Brandwidth Solutions LLC Chris Anderson +1 207 232 7007
canderson@brandwidthsolutions.com
Berkeley Lights (NASDAQ:BLI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Berkeley Lights (NASDAQ:BLI)
Historical Stock Chart
From Apr 2023 to Apr 2024